D0816L00003:Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy

February 19, 2019
Cancer - Ovarian
Cancer, Relapsed Ovarian Cancer, Ovarian Cancer, Ovarian, BRCA mutations, mutations, Phase 2, Phase II, Ancillary, Fallopian, Epithelial